154 related articles for article (PubMed ID: 21718233)
1. Progress of antiplatelet pharmacogenomics.
Oestreich JH
Curr Drug Targets; 2011 Nov; 12(12):1848-58. PubMed ID: 21718233
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomics of clopidogrel: evidence and perspectives.
Yin T; Miyata T
Thromb Res; 2011 Oct; 128(4):307-16. PubMed ID: 21592545
[TBL] [Abstract][Full Text] [Related]
3. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
[TBL] [Abstract][Full Text] [Related]
4. Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention.
Desai NR; Canestaro WJ; Kyrychenko P; Chaplin D; Martell LA; Brennan T; Matlin OS; Choudhry NK
Circ Cardiovasc Qual Outcomes; 2013 Nov; 6(6):694-9. PubMed ID: 24192573
[TBL] [Abstract][Full Text] [Related]
5. Current status of clopidogrel pharmacogenomics.
Giusti B; Gori AM; Marcucci R; Abbate R
Pharmacogenomics; 2012 Nov; 13(15):1671-4. PubMed ID: 23171330
[No Abstract] [Full Text] [Related]
6. Pharmacogenetics of clopidogrel.
O'Connor SA; Hulot JS; Silvain J; Cayla G; Montalescot G; Collet JP
Curr Pharm Des; 2012; 18(33):5309-27. PubMed ID: 22724417
[TBL] [Abstract][Full Text] [Related]
7. The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects.
Umemura K; Furuta T; Kondo K
J Thromb Haemost; 2008 Aug; 6(8):1439-41. PubMed ID: 18532997
[No Abstract] [Full Text] [Related]
8. Clopidogrel hyporesponsiveness and the FDA boxed warning: detection and management of patients with genetic polymorphisms.
Perry E
Am J Health Syst Pharm; 2011 Mar; 68(6):529-32. PubMed ID: 21378302
[No Abstract] [Full Text] [Related]
9. [Pharmacogenetics of clopidogrel and its clinical significance].
Panchenko EP; Komarov AL
Kardiologiia; 2012; 52(9):44-52. PubMed ID: 23098546
[TBL] [Abstract][Full Text] [Related]
10. Genetic causes of clopidogrel nonresponsiveness: which ones really count?
Momary KM; Dorsch MP; Bates ER
Pharmacotherapy; 2010 Mar; 30(3):265-74. PubMed ID: 20180610
[TBL] [Abstract][Full Text] [Related]
11. PON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivity.
Li X; Zhang L; Chen X; Qu F; Li J; Ma C; Yang J; Xu B; Wang H; Xu Q; Zhang Y; Li Y; Lu C; Yin T
Thromb Res; 2013 Oct; 132(4):444-9. PubMed ID: 23993903
[TBL] [Abstract][Full Text] [Related]
12. Clopidogrel and genetic testing: is it necessary for everyone?
Goswami S; Cheng-Lai A; Nawarskas J
Cardiol Rev; 2012; 20(2):96-100. PubMed ID: 22293861
[TBL] [Abstract][Full Text] [Related]
13. The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.
Price MJ; Tantry US; Gurbel PA
Rev Cardiovasc Med; 2011; 12(1):1-12. PubMed ID: 21546883
[TBL] [Abstract][Full Text] [Related]
14. Laboratory evaluation of clopidogrel responsiveness by platelet function and genetic methods.
Smock KJ; Saunders PJ; Rodgers GM; Johari V
Am J Hematol; 2011 Dec; 86(12):1032-4. PubMed ID: 21812020
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.
Giusti B; Gori AM; Marcucci R; Saracini C; Sestini I; Paniccia R; Valente S; Antoniucci D; Abbate R; Gensini GF
Pharmacogenet Genomics; 2007 Dec; 17(12):1057-64. PubMed ID: 18004210
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of genetically determined platelet reactivity.
Laine M; Arméro S; Peyrol M; Sbragia P; Thuny F; Paganelli F; Bonello L
J Cardiovasc Transl Res; 2013 Jun; 6(3):398-403. PubMed ID: 23149816
[TBL] [Abstract][Full Text] [Related]
17. Clopidogrel resistance: pharmacokinetic or pharmacogenetic?
Ford NF
J Clin Pharmacol; 2009 May; 49(5):506-12. PubMed ID: 19246723
[TBL] [Abstract][Full Text] [Related]
18. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.
Scott SA; Sangkuhl K; Stein CM; Hulot JS; Mega JL; Roden DM; Klein TE; Sabatine MS; Johnson JA; Shuldiner AR;
Clin Pharmacol Ther; 2013 Sep; 94(3):317-23. PubMed ID: 23698643
[TBL] [Abstract][Full Text] [Related]
19. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping.
Alexopoulos D; Dimitropoulos G; Davlouros P; Xanthopoulou I; Kassimis G; Stavrou EF; Hahalis G; Athanassiadou A
JACC Cardiovasc Interv; 2011 Apr; 4(4):403-10. PubMed ID: 21511219
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study.
Gladding P; White H; Voss J; Ormiston J; Stewart J; Ruygrok P; Bvaldivia B; Baak R; White C; Webster M
JACC Cardiovasc Interv; 2009 Nov; 2(11):1095-101. PubMed ID: 19926050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
